US › Healthcare

DBV Technologies (DBVT)

US · Healthcare · Biotechnology

$13.71+0.96%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-50.4M
Profit YoY
-18.9%
EPS
$-0.60
EPS estimate
$-0.12

EPS came in at -0.60 against a street estimate of -0.12 — a miss of 400.0%.

Key statistics

Market cap
$799.0M
Forward P/E
0.0
P/B
4.98
Book value
$2.71
EPS (TTM)
$-3.50
52-week high
$26.18
52-week low
$8.66
50-day MA
$16.18
200-day MA
$18.24
Beta
-0.21

Analyst view

Analysts rate DBV Technologies a hold (2 buy, 0 hold, 1 sell out of 3) with an average price target of $40.90.

Shareholding

Institutions
37.12%

Largest institutional holders

FundStake
MPM Oncology Impact Management LP8.81%
Vivo Capital, LLC4.51%
Artisan Partners Limited Partnership3.75%
Siren, L.L.C.3.14%
Baker Bros Advisors LP2.47%
ADAR1 Capital Management LLC1.71%
Perceptive Advisors LLC1.63%
Patient Square Capital LP1.17%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for DBV Technologies — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.